Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus delta NS1 vaccine

Drug Profile

Influenza virus delta NS1 vaccine

Alternative Names: deltaFLU LAIV; deltaFLU quadrivalent LAIV; FluVacc; FluVacc - DNS1; Fluvacc delta NS1; FLUVACCdelNS1; FluVaccΔNS1; GHB01L1; GHB04L1; GHB11L1; GHB16L2; H5N1 influenza virus vaccine; Influenza A virus vaccine H1N1; Intranasal H5N1 vaccine - Avir Green Hills Biotechnology; Pandemic avian flu vaccine - Avir Green Hills Biotechnology; Seasonal influenza vaccine deltaFLU; Seasonal influenza virus vaccine Green Hills - Biotechnology

Latest Information Update: 03 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Hills Biotechnology
  • Developer Vivaldi Biosciences
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 03 Sep 2021 Vivaldi Biosciences plans a phase II trial for Influenza virus infection (Vivaldi Biosciences pipeline, September 2021)
  • 12 Oct 2018 Influenza virus delta NS1 vaccine is still in phase II trials for Influenza virus infections in Austria (Vivaldi Biosciences product development, October 2018)
  • 04 Apr 2018 Pharmacodynamics data from a preclinical study in Influenza virus infections released by Vivaldi Biosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top